Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis SA (OTC Pink: BPTSY) has entered exclusive negotiations with a leading Chinese pharmaceutical company to establish a licensing agreement for BIO101 (20-Hydroxyecdysone). The agreement aims to co-develop and commercialize BIO101 in China for treating viral respiratory infections, sarcopenia, and obesity.
The potential partner is part of a major Chinese group with expertise in innovative technologies and access to China's rapidly growing market. This development follows Biophytis' partnership strategy, building on their previous agreement with Blanver for the LATAM region. The Chinese market represents a significant opportunity, with 70 million obesity patients and 30 million sarcopenia patients. China is currently the second-largest pharmaceutical market globally, valued at $190 billion.
Biophytis SA (OTC Pink: BPTSY) ha avviato trattative esclusive con una delle principali aziende farmaceutiche cinesi per stabilire un accordo di licenza per BIO101 (20-Idrossiecdisterone). L'accordo mira a co-sviluppare e commercializzare BIO101 in Cina per il trattamento delle infezioni respiratorie virali, della sarcopenia e dell'obesità.
Il partner potenziale fa parte di un importante gruppo cinese con esperienza in tecnologie innovative e accesso al mercato in rapida crescita della Cina. Questo sviluppo segue la strategia di partnership di Biophytis, basandosi sul loro precedente accordo con Blanver per la regione LATAM. Il mercato cinese rappresenta un'opportunità significativa, con 70 milioni di pazienti obesi e 30 milioni di pazienti affetti da sarcopenia. La Cina è attualmente il secondo mercato farmaceutico più grande al mondo, con un valore di 190 miliardi di dollari.
Biophytis SA (OTC Pink: BPTSY) ha iniciado negociaciones exclusivas con una importante compañía farmacéutica china para establecer un acuerdo de licencia para BIO101 (20-Hidroxiecdisterona). El acuerdo tiene como objetivo co-desarrollar y comercializar BIO101 en China para tratar infecciones respiratorias virales, sarcopenia y obesidad.
El socio potencial forma parte de un gran grupo chino con experiencia en tecnologías innovadoras y acceso al mercado de rápida expansión de China. Este desarrollo sigue la estrategia de asociación de Biophytis, fundamentándose en su acuerdo previo con Blanver para la región de LATAM. El mercado chino representa una oportunidad significativa, con 70 millones de pacientes obesos y 30 millones de pacientes con sarcopenia. China es actualmente el segundo mercado farmacéutico más grande del mundo, valorado en 190 mil millones de dólares.
Biophytis SA (OTC Pink: BPTSY)는 주요 중국 제약 회사와 BIO101 (20-하이드록시에카디스톤)에 대한 라이센스 계약 체결을 위한 독점 협상에 들어갔습니다. 이 계약은 중국에서 바이러스성 호흡기 감염, 근감소증 및 비만 치료를 위해 BIO101을 공동 개발하고 상용화하는 것을 목표로 하고 있습니다.
잠재적인 파트너는 혁신 기술에 대한 전문성과 중국의 급성장하는 시장에 대한 접근을 갖춘 주요 중국 그룹의 일부입니다. 이 개발은 Biophytis의 파트너십 전략을 따르며, LATAM 지역의 Blanver와의 이전 계약을 기반으로 하고 있습니다. 중국 시장은 7000만 명의 비만 환자와 3000만 명의 근감소증 환자가 있는 중요한 기회를 제공합니다. 현재 중국은 1900억 달러로 평가되는 세계에서 두 번째로 큰 제약 시장입니다.
Biophytis SA (OTC Pink: BPTSY) a engagé des négociations exclusives avec une grande entreprise pharmaceutique chinoise pour établir un accord de licence pour BIO101 (20-Hydroxyecdystérone). Cet accord vise à co-développer et commercialiser BIO101 en Chine pour traiter les infections respiratoires virales, la sarcopénie et l'obésité.
Le partenaire potentiel fait partie d'un grand groupe chinois disposant d'une expertise en technologies innovantes et d'un accès à ce marché chinois en forte croissance. Ce développement s'inscrit dans la stratégie de partenariat de Biophytis, s'appuyant sur leur précédent accord avec Blanver pour la région LATAM. Le marché chinois représente une opportunité significative, avec 70 millions de patients obèses et 30 millions de patients atteints de sarcopénie. La Chine est actuellement le deuxième marché pharmaceutique mondial, évalué à 190 milliards de dollars.
Biophytis SA (OTC Pink: BPTSY) hat exklusive Verhandlungen mit einem führenden chinesischen Pharmaunternehmen aufgenommen, um eine Lizenzvereinbarung für BIO101 (20-Hydroxyecdysteron) zu etablieren. Ziel dieser Vereinbarung ist es, BIO101 in China zur Behandlung von viralen Atemwegsinfektionen, Sarkopenie und Fettleibigkeit gemeinsam zu entwickeln und zu vermarkten.
Der potenzielle Partner gehört zu einem großen chinesischen Konzern, der über Fachwissen in innovativen Technologien und Zugang zum schnell wachsenden Markt Chinas verfügt. Diese Entwicklung folgt der Partnerschaftsstrategie von Biophytis und baut auf ihrer vorherigen Vereinbarung mit Blanver für die LATAM-Region auf. Der chinesische Markt stellt eine bedeutende Gelegenheit dar, mit 70 Millionen Adipositas-Patienten und 30 Millionen Sarkopenie-Patienten. China ist derzeit der zweitgrößte Pharmamarkt weltweit, bewertet auf 190 Milliarden Dollar.
- Entry into Chinese market, world's second-largest pharmaceutical market ($190 billion)
- Large target patient population in China (70M obesity, 30M sarcopenia patients)
- Strategic expansion following successful LATAM partnership with Blanver
- Agreement still in negotiation phase, not finalized
- Terms and financial details of potential deal not disclosed
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in China for its most promising and advanced indications: viral respiratory infections, sarcopenia, and obesity.
The pharmaceutical company is part of an important Chinese group and stands out for its expertise in the development of innovative technologies and its ability to access a rapidly growing market.
"The entry into exclusive discussions with this pharmaceutical company marks a major first step, validating our partnership strategy in continuity with the agreement signed with Blanver for the LATAM region. The opportunity in China is huge, with obesity affecting 70 million patients and sarcopenia nearly 30 million. China is now the second-largest pharmaceutical market in the world, valued at
"This partnership could enable us to enter a new era for the company by finalizing the development of BIO101, allowing millions of patients to benefit from our therapeutic innovation," said Stanislas Veillet, CEO of Biophytis.
* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Biophytis contacts
Relations Investisseurs
Investors@biophytis.com
US Investors
Pascal Nigen – Alpha Bronze
pnigen@alphabronzellc.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr – +33 6 16 16 51 78
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236977
FAQ
What is the potential market size for BPTSY's BIO101 in China?
What medical conditions will BPTSY's BIO101 target in the Chinese market?
How does this Chinese partnership align with BPTSY's existing business strategy?
What is the current status of BPTSY's licensing agreement in China?
